Drug Related Genetic Polymorphisms Affecting Adverse Reactions to Methotrexate, Vinblastine, Doxorubicin and Cisplatin in Patients With Urothelial Cancer

Journal of Urology

Volumn 180, Issue 6, 2008, Pages 2389-2395

  Tsuchiya, Norihiko ^a   Inoue, Takamitsu ^a   Narita, Shintaro ^a   Kumazawa, Teruaki ^a   Saito, Mitsuru ^a   Obara, Takashi ^a   Tsuruta, Hiroshi ^a   Horikawa, Yohei ^a   Yuasa, Takeshi ^a   Satoh, Shigeru ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

adverse effects; antineoplastic agents; genetic; neoplasms; polymorphism; urothelium

Indexed keywords

CISPLATIN; CYTOCHROME P450 3A5; DOXORUBICIN; GLUTATHIONE TRANSFERASE P1; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; VINBLASTINE;

ADULT; AGED; ALLELE; ANEMIA; ANOREXIA; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; UROGENITAL TRACT TUMOR; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; UROLOGIC NEOPLASMS; VINBLASTINE;

EID: 55549145738     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.08.035     Document Type: Article

References (23)

1. Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Geller N., Herr H.W., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64 (1989) 2448
2. Freimuth R.R., Xiao M., Marsh S., Minton M., Addleman N., Van Booven D.J., et al. Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet 14 (2005) 3595
3. Massacesi C., Terrazzino S., Marcucci F., Rocchi M.B., Lippe P., Bisonni R., et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106 (2006) 1007
4. Allan J.M., Wild C.P., Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A 98 (2001) 11592
5. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18 (2001) 1400
6. Stoehlmacher J., Park D.J., Zhang W., Groshen S., Tsao-Wei D.D., Yu M.C., et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94 (2002) 936
7. Kivisto K.T., Kroemer H.K., and Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40 (1995) 523
8. Tsuchiya N., Satoh S., Tada H., Li Z., Ohyama C., Sato K., et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78 (2004) 1182
9. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111
10. Sternberg C.N., de Mulder P.H., Schornagel J.H., Theodore C., Fossa S.D., van Oosterom A.T., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19 (2001) 2638
11. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383
12. Roy J.N., Lajoie J., Zijenah L.S., Barama A., Poirier C., Ward B.J., et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 33 (2005) 884
13. Yamaori S., Yamazaki H., Iwano S., Kiyotani K., Matsumura K., Honda G., et al. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19 (2004) 120
14. Lin Y.S., Dowling A.L., Quigley S.D., Farin F.M., Zhang J., Lamba J., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62 (2002) 162
15. Wegman P., Elingarami S., Carstensen J., Stal O., Nordenskjold B., and Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9 (2007) R7
16. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., and Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25 (2007) 4528
17. Watson M.A., Stewart R.K., Smith G.B., Massey T.E., and Bell D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19 (1998) 275
18. Geisler S.A., Olshan A.F., Cai J., Weissler M., Smith J., and Bell D. Glutathione S-transferase polymorphisms and survival from head and neck cancer. Head Neck 27 (2005) 232
19. Sweeney C., Nazar-Stewart V., Stapleton P.L., Eaton D.L., and Vaughan T.L. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12 (2003) 527
20. Efferth T., and Volm M. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo 19 (2005) 225
21. Robert J., Morvan V.L., Smith D., Pourquier P., and Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54 (2005) 171
22. Yokomizo A., Yamamoto K., Kinukawa N., Tsunoda T., Koga H., and Naito S. Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy. Int J Urol 14 (2007) 500
23. Rosenberg J.E., Carroll P.R., and Small E.J. Update on chemotherapy for advanced bladder cancer. J Urol 174 (2005) 14